# Council Memo — 2026-11-02

*This is a structured synthesis of your own agents' analysis, not licensed investment advice.
Every number comes from this sweep's snapshot (`20261102T061301.json`), candidates CSV
(`20261102T061621-candidates.csv`), scout JSON health block, `candidate_history.csv`,
the calendar file (`20261102-events.json`), `portfolio.json`, `investor_profile.json`, or
the four lens outputs relayed this session. Anything else is labelled: carried from the
2026-10-26 memo, or my own arithmetic.*

*The Council is still not weighted (JUDGEMENT pillar needs a second consecutive n=20+
reading, per OPEN_ITEMS.md). I judged the arguments on their quality. Vote counts and
mechanical rank played no part (S33).*

---

## What leads this memo

**1. ABB.ST: the SELL is retired. Final call: NO ACTION (hold 4 shares, add nothing).
Conviction 5, confidence Low.** This is a fresh decision, not the old call lapsing by
default. Full reasoning in #1 below. In short:
- Three facts originally carried the SELL. Two of them turned out to be data artifacts in
  earlier sweeps (S32). The third ("richest PEG of the trio", 2.71) has flipped: PEG is now
  1.24, the lowest of ATCO 1.94 / ALFA 1.67 / ABB 1.24.
- **One correction to `thesis-review`.** It presents the reversal as new evidence. It
  mostly is not. Last week's memo already conceded PEG ~1.2, and the forward/trailing gap
  is the same ~1.6% both weeks (31.01/31.51 then, 32.33/32.86 now). The only thing that
  changed this week is the price: **825.60 → 878.00, +6.3%**. So the honest question is
  whether last week's SELL was right on the evidence it already had. I now judge it was
  not, partly because its funding destination (VICI) weakened this week (#4).
- Record update for you (no agent edits it): ABB.ST `thesis_status` BROKEN → WEAKENING.

**2. The Riksbank decides on 2026-11-04, in two days.** The 1.75% policy rate and the +0.65pp
real-rate reading (SE CPI 1.1%) used everywhere below may be out of date by Wednesday.
- This touches SHB-A.ST (a queued BUY), all three Swedish property candidates and,
  indirectly, the Swedish sleeve (47.6%, ACT).
- APP, FIS and TPL report the same day, and SMCI reports on 11-03 (§8).
- No call below rests on guessing the decision. The only change is sequencing: the SHB buy
  comes after 11-04.

**3. Process (S27): an 11th-plus occurrence, reported by the orchestrator.** The launch
prompt again claimed that (a) the Handelsbanken wrapper is unresolved and (b)
`reference_targets` are null. Both are false.
- The wrapper was closed 2026-08-03 (`portfolio.json` `exit_plans.hb-af-exit`: FULLY
  EXECUTED).
- `investor_profile.json.reference_targets` reads 85/10/0/5 with no `gold_pct`. I verified
  this myself this session. That is S35, not null.
- The orchestrator declined both premises before anything ran. I note it and move on.

---

## 1. Position report

**I could not run `scripts/position_report.py`. This agent has no shell.** The table below
rebuilds it from the candidates CSV prices × `portfolio.json` quantities, compared with the
2026-10-26 run in `candidate_history.csv`. All of it is my arithmetic. Run the script to
confirm.

| Position | Price | Δ vs prev run | Δ vs cost | 52w range | Value (SEK) | Source |
|---|---|---|---|---|---|---|
| Handelsbanken A | 155.75 | +5.5% | +20.5% | 95% | 155.75 | fetched |
| Investor A | 419.70 | +4.1% | +44.6% | 97% | 2,098.50 | fetched |
| Volvo B | 310.10 | −0.4% | −15.6% | 46% | 4,031.30 | fetched |
| Atlas Copco B | 164.20 | +4.7% | −9.4% | 58% | 4,433.40 | fetched |
| AstraZeneca | 1,720.50 | +0.4% | +11.9% | 55% | 13,764.00 | fetched |
| Alfa Laval | 550.00 | +1.7% | −4.2% | 73% | 4,950.00 | fetched |
| ABB | 878.00 | +6.3% | −7.3% | 57% | 3,512.00 | fetched |
| Xetra-Gold (DE000A0S9GB0) | no data | — | — | — | 5,689.22 | FETCH FAILED (429/404), at cost |
| Avanza Auto 3 | no data | — | — | — | 16,191.00 | book value (NAV dated 2026-07-24) |
| Avanza Global | no data | — | — | — | 119,999.00 | book value (2026-07-28) |
| Valour Bitcoin Zero (BTC0E.AS) | no data | — | — | — | 11,031.00 | FETCH FAILED, mark 2026-08-21 |
| ETH (0.50185) | 22,726.98 SEK/ETH | −1.2% | no basis (P1) | — | 11,405.53 | CoinGecko 2,044.97 EUR × 11.1136 |

Crypto context: bitcoin 69,952 EUR (7d −2.1%, 30d −7.3%, −35.0% vs ATH); ethereum 2,044.97
EUR (30d −14.4%, −51.7% vs ATH). Fear & Greed is 37 ("Fear"), down from 50.

**What moved, and whether it matters:**
- **The direct stock sleeve rose to 32,944.95 SEK.** The four industrials gained +476.10
  between them (16,450.60 → 16,926.70). ABB (+6.3%) and ATCO (+4.7%) led. Volvo was the only
  one that fell (−0.4%), and that was the week its board member put ~466M SEK into the
  stock (§3a Copycat).
- **No price move contradicts a thesis.** AZN reported on 10-30, and the snapshot fields
  moved in a way consistent with that: operating margin is **29.6%**, up from 23.5% in last
  week's memo, and ND/EBITDA is 1.23. Both tests the Council set for that print passed
  (Defensive: op margin ≥20%; Valuation: PEG ≤1.6, now 1.28).
- **SHB and INVE are at 95% and 97% of their 52-week ranges.** That is captured upside.
  Both are discussed below.
- **Index funds:** about 136k SEK is held at marks 14–15 weeks old. That is a pricing gap,
  not a thesis issue (§9).

---

## 2. Scout health

```
Universe: 624 | Fetched: 621 (cache 579, new 46, failed 4) | Ranked: 613 | Candidates: 73 (holdings 9, watchlist 30, new 34) | Focus: 24 | Screened: 73 | Passed: 37 | Missing: 17 | Failed: 19 | Status: VALID
```

**Reading: VALID, on the second run.** The first run came back DEGRADED because the universe
was 34 days old. After this morning's refresh (+3/−3 names) it came back clean. Nothing
upstream needs distrusting before §3. Three caveats:
- **579 of the 621 fetches came from cache**, presumably the first run's same-morning
  fetch. I have not verified that, but nothing suggests stale fundamentals.
- **Four fetches failed.** BTC0E.AS and DE000A0S9GB0 are standing gaps. BF.B and FING-B.ST
  returned 404 for the first time.
- **Six suspect values were withheld from the lens scores** (SNDK/MU `revenue_growth`,
  INDU-C.ST op margin, TSM ROIC, ASML P/B and ROIC, KINV-B.ST P/S). None is reasoned from
  below. TSM's `fcf_yield_pct` of 57.12% is still **unflagged** (S32), and I do not use it.

**`source=new` does not mean "first seen", and this sweep shows it at its starkest.** Per the
orchestrator's check against all 12 runs, **zero of 34** `new` rows are first-seen. 33 of
them were already present on 10-26. I confirmed the 10-26 presence for the names I use
(APP, VICI, FIX, WIHL.ST, CATE.ST, DIOS.ST, SMCI, FIS, TPL). Discovery found nothing
genuinely new this week. That is a Pillar-1 finding, and it goes to `meta` (§9).

**VICI: the "purely mechanical" framing is wrong this week.** VICI fell from rank 13 to rank
28. The relayed context calls this a price effect only. The fundamentals rows say otherwise
(10-26 memo → today):
- trailing P/E 9.25 → **11.32** while the price rose only 24.02 → 24.52 (+2.1%). That
  implies trailing EPS fell ~17% (my arithmetic).
- net margin 67.5% → **56.5%**
- ND/EBITDA 4.82 → **5.46**

Something in VICI's reported numbers changed. See #4.

---

## 3. Top opportunities

### 3a. The seven voices (independent passes)

Each voice triaged all 73 rows on its own columns before drafting. A pick pulled in from
outside `focus=Y` is labelled as such.

#### Voice 1 — Fundamental / Quality

*Triage (`z_quality`):* SNDK 2.557, APP 2.532, NVDA 2.541, MU 2.455, MA 2.249, V 1.924, TPL
1.760, AZA.ST 1.733, AAPL 1.654, LLY 1.626, MO 1.552, TSM 1.499. *Moat, management and
capital allocation are in no fetched field; I judge them qualitatively and say so.*

- **BUY V, 8.**
  - Why: ROIC 41.5%, ROE 63.5%, margins 51.2/63.7, ND/EBITDA 0.25, revenue +13.2% on a
    12.0% CAGR.
  - Revenue growth slipped from 14.4% last week, which is the only movement.
  - Risk: interchange regulation (qualitative).
  - Invalidated by: ROIC below 30%, or revenue growth below the 12% CAGR for two runs.
- **BUY MA, 7 (against its FAIL).**
  - Why the FAIL misleads: D/E 355 is buyback-driven negative equity. ND/EBITDA is 0.59.
  - Underneath: ROIC 56.6%, margins 46.7/60.5, revenue +14.0%.
  - Invalidated by: ND/EBITDA above 2.0.
- **BUY NVDA, 7.**
  - Why: ROIC 59.2%, ROE 117.2%, op margin 66.2%, net cash (−0.12).
  - Held at 7: FCF yield 0.85% against an earnings yield of 3.87% (1/25.87). About 22% of
    earnings reaches free cash.
  - Invalidated by: FCF yield still below 1% after the **11-17** print.
- **BUY ATCO-B.ST (holding), 7.**
  - Why: ROIC 38.5%, op margin 20.8%, ND/EBITDA 0.3, FCF yield 3.32% (SEK over SEK, so
    clean). Ttm revenue +15.1% holds for a second run.
  - Invalidated by: ttm revenue turning negative.
- **BUY APP, 6 (new this week, on consistency).**
  - Last week I declined APP for "leverage-inflated ROE" while buying MA, whose D/E is
    worse. Applied consistently, my test says APP is not leveraged in the sense that
    matters: **ND/EBITDA 0.09**. D/E 111 reflects a small equity base, as with MA.
  - Underneath: ROIC 65.5%, op margin 77.7%, FCF yield 4.14% against an earnings yield of
    5.69% (~73% conversion).
  - Risk: the price has fallen to 6% of range and no file explains why. Quality is a fact
    about the business, not a clearance on whatever the market is pricing.
  - Invalidated by: op margin below 60% at the 11-04 print.
- **ABB.ST: no SELL.** ROIC 23.3%, op margin 18.7%, ND/EBITDA 0.32. Quality is not the
  problem with this holding.
- **Declined:**
  - **SNDK/MU.** Op margins 79.6/80.7 and suspect growth: peak-cycle numbers.
  - **TPL.** The forward figure is not credible.
  - **AZA.ST.** Forward 27.1 vs trailing 19.2 implies ~−29% EPS.

#### Voice 2 — Valuation

*Triage (`z_value`):* CHTR 1.900, CMCSA 1.839, FIS 1.767, ALL 1.690, CORE-B.ST 1.638, DOM.ST
1.623, FISV 1.557, EG 1.517, GM 1.495, BURE.ST 1.436, UHS 1.430, DIOS.ST 1.238, INDU-C.ST
1.242. *Named gap: no EV/EBITDA or EV/EBIT. Where I lean on ND/EBITDA, I say so.*

- **BUY NVDA, 7.**
  - Why: forward 12.86 against trailing 25.87 on +105.9% revenue. The forward multiple fell
    for a third week (13.45 → 13.26 → 12.86) while the price barely moved (+0.7%).
  - I do not rely on PEG 0.25.
  - Invalidated by: forward rising above trailing.
- **BUY VOLV-B.ST (holding), 6.**
  - Why: forward 12.45 against trailing 16.14 prices a ~30% EPS rise. PEG 0.85, 3.86% FCF
    yield, 2.74% dividend, at 46% of range.
  - Risk: ND/EBITDA 3.69. That is the watch item, not the multiple.
  - Invalidated by: forward rising to meet trailing.
- **BUY AZN.ST (holding), 6.**
  - Why: PEG 1.28 after the print (my bar was ≤1.6).
  - Missing: `forward_pe` for the 11th consecutive run (S21). The raw P/S, P/B and FCF yield
    are S32 unit errors and I do not use them.
  - Invalidated by: PEG above 1.6.
- **SELL ABB.ST, 3 (down from 4).**
  - Why: 32.86x trailing and 32.33x forward are still the richest pair held. The flat gap
    still means flat expected EPS on 14.3% revenue growth.
  - My own concession, louder this week: on a growth-adjusted basis (PEG 1.24) ABB is the
    cheapest of the three non-Volvo industrials. The +6.3% week made it pricier in absolute
    terms but changed nothing else.
- **VICI: BUY withdrawn.**
  - Trailing P/E rose 9.25 → 11.32 on a +2.1% price move, so trailing EPS fell ~17%.
    ND/EBITDA rose 4.82 → 5.46, toward my own invalidation line of 6.
  - A falling-EPS, rising-leverage REIT at 8.18x forward is not the margin of safety I
    bought it for. No FFO/AFFO is available to tell me whether this is an accounting item.
- **Examined, not picked:**
  - **FIS.** PEG 0.2 is inconsistent with a forward of 5.80 vs a trailing of 5.92 (only
    ~+2% EPS). Net margin 27.6% *exceeds* op margin 20.7%, so a non-operating gain is
    probably flattering the trailing P/E. ND/EBITDA 5.82.
  - **UHS.** 7.4x, 7.2% FCF yield, but forward slightly above trailing, and hospital
    policy risk is in no file. One run of evidence.
  - **CHTR/CMCSA.** Revenue −1.7%/−6.1%.
  - **ALL.** Forward 9.24 vs 5.20.
  - **AVGO.** 16.75 vs 41.64 looks like a GAAP-vs-adjusted basis gap, not +149% EPS.
  - **WIHL/CATE/DIOS.** ND/EBITDA ~10–11.

#### Voice 3 — Growth / Opportunity

*Triage (`z_growth`):* NVDA 1.936, SMCI 1.790, AVGO 1.771, APO 1.732, BE 1.693, FIX 1.587,
AXON 1.573, MU 1.494, DASH 1.461, APP 1.452, AMD 1.422, LLY 1.322.
*Forward below trailing, cleanest:* NVDA 12.86/25.87, APP 11.42/17.56, FIX 18.45/26.62,
VOLV 12.45/16.14, META 17.36/20.98.
*Not trusted:* SNDK 3.99/9.20 and MU 4.26/11.90 (suspect growth), TPL, GM, AVGO, APO, BE,
AXON, DASH.
*Named gaps: no TAM, revisions or market-share data.*

- **BUY NVDA, 8.**
  - Why: +105.9% on a 100.0% CAGR, forward at half of trailing and still compressing.
  - Risk: a hyperscaler capex pause (qualitative). The candidate set is crowded with the
    same AI-capex exposure (AVGO, MU, SNDK, SMCI, TSM).
  - Invalidated by: growth below 40% at 11-17, or forward above trailing.
- **BUY FIX, 6 (pulled in, rank 24).**
  - Why: +53.7% on a 30.0% CAGR, forward 18.45 vs 26.62, FCF yield 4.91% against a 3.76%
    earnings yield, net cash (−0.81).
  - Third run of the pattern, with the price back up +3.7%.
  - Risk: beta 1.659.
  - Invalidated by: growth below 25%.
- **BUY VOLV-B.ST (holding), 6.** Ttm revenue +8.0% holds for a second run, from −13% over
  two fiscal years. The forward multiple still prices a ~30% EPS rise.
- **BUY APP, 5.**
  - Why: +52.8% revenue at a 77.7% op margin, and consensus still prices EPS +54% (forward
    11.42 vs 17.56).
  - Against: the price is at 6% of range, down a third week (279.29 → 264.28 → 254.91).
  - The 11-04 print settles which side is wrong.
- **SELL SHB-A.ST, 3.** Revenue −2.1%, forward 13.64 above trailing 13.24, z_growth −1.079.
  Unchanged.
- **Declined:**
  - **SMCI.** FCF yield −38.1%.
  - **AVGO.** Acquisition base effect.
  - **META.** Second down week with no explanation in any file.
  - **CATE.ST.** Revenue +25.5%, but forward 13.84 vs 9.91 implies EPS −28%. Trailing
    likely includes property revaluations.

#### Voice 4 — Defensive / Risk

*Triage (lowest `beta`):* SAAB-B.ST 0.03, ALL 0.138, BETS-B.ST 0.17, JNJ 0.206, AZN.ST 0.212,
ABBV 0.228, EG 0.259, KO 0.318, TEL2-B.ST 0.34, PEP 0.364, PG 0.377, NOVO-B.CO 0.384, SEB-A.ST
0.441, MO 0.461, SHB-A.ST 0.493.

**The scenarios I position for:**
- **A Riksbank surprise on 11-04.** A Swedish rate shock hits banks, levered property and
  cyclicals together. That is about half of your direct sleeve.
- **An AI-capex unwind.** Six of the twelve highest-z names in this file share that one
  driver.

VIX fell 19.03 → 17.20. Calm is when defensives are cheapest to own, not a reason to drop
them.

- **BUY AZN.ST (holding), 7.**
  - Why: beta 0.212, ND/EBITDA 1.23, op margin 29.6% after the 10-30 print, revenue +6.7%,
    55% of range.
  - My test last week was op margin ≥20% at the print. It passed with room.
  - Invalidated by: a dividend cut, or op margin below 20%.
- **BUY NOVO-B.CO, 4 (pulled in, rank 43).**
  - Why: beta 0.384, ND/EBITDA 0.55, ROIC 35.6%, net margin 35.3%, P/E 10.16, 4.4% dividend,
    19% of range.
  - Risk: forward 11.97 above trailing implies EPS ~−15%, and revenue is only +2.1%. This is
    stability at a low price, not growth.
- **BUY PEP, 4 (pulled in, rank 63).**
  - Why: beta 0.364, 4.31% dividend, forward 15.90 below trailing 17.28. The price fell
    3.6% this week, back to 21% of range.
  - Risk: D/E 230.7 is high for a staple, though ND/EBITDA is 2.12.
- **SELL VOLV-B.ST, 3 (down from 4).** D/E 140.9 and ND/EBITDA 3.69 at beta 1.0: still the
  most leveraged holding in the most cyclical sleeve. Lower than last week because revenue
  has recovered for two runs.
- **Attacking this sweep's BUY cases:**
  - **NVDA/APP/FIX.** Betas 2.216 / 2.557 / 1.659.
  - **SHB.** At 95% of range the cushion I bought it for last week has thinned. The yield
    is now 5.14%.
  - **WIHL/CATE/DIOS.** ~10x ND/EBITDA two days before a rate decision.
  - **VICI.** Leverage rising.
- **Not flagging ABB.ST.** ND/EBITDA 0.32. There is no risk case.

#### Voice 5 — Contrarian / Risk Taker

*Triage (`pct_52w_range`):* CHTR 5, APP 6, WIHL.ST 6, CORE-B.ST 7, FSLR 7, GOOGL 10, DOM.ST
11, CATE.ST 13, CMCSA 14, FIS 14, DIOS.ST 16, FISV 17, EXE 17, NOVO-B.CO 19, PEP 21, TPL 21.

- **BUY APP, 5.**
  - Why the pessimism looks wrong on the data: three straight down weeks to 6% of range,
    yet the business fields are unchanged (op margin 77.7%, ND/EBITDA 0.09, FCF yield
    4.14%) and estimates still price EPS +54%.
  - The price and the fundamentals disagree, and the 11-04 print resolves it.
  - Risk: the market knows something no file holds (S29: 52w endpoints only).
  - Invalidated by: the print cutting forward estimates, i.e. the forward multiple rising
    toward trailing.
- **BUY NOVO-B.CO, 4.**
  - Why: at 10.2x trailing with a 35.3% net margin, the price discounts more than the ~15%
    EPS decline the forward implies.
  - Invalidated by: revenue turning negative.
- **BUY GOOGL, 3 (pulled in, rank 44).**
  - Why: −18.7% in two weeks (349.22 → 283.82, my arithmetic on `candidate_history.csv`),
    now at 10% of range.
  - Why I think the read is partly wrong: forward 18.44 sits *above* trailing 14.61, but net
    margin 50.0% far exceeds op margin 31.8%. The trailing figure is likely flattered by
    non-operating gains, so the forward is the cleaner read. 18.4x for +24.7% revenue
    (accelerating, above the 12.5% CAGR) is not expensive.
  - The real bear point: FCF yield −0.03%, meaning capex consumes all operating cash.
  - Invalidated by: a second negative-FCF print with revenue growth slowing below 15%.
- **Retired:**
  - **FSLR.** The third run broke the pattern: revenue −3.7% → −22.8%, FCF yield 8.65% →
    3.67%.
  - **VICI.** My invalidation (price falling while the 10-year falls) did not fire. But
    trailing EPS −17% and margin −11pp is a fundamentals change I cannot explain without
    the print, so the BUY does not hold.
- **SELL flags: none.**
- **Declined, penalty deserved:**
  - **WIHL/CATE/DIOS.** Still 10x ND/EBITDA, and the Riksbank on 11-04 is the observable.
    Re-test next sweep with the decision in the data.
  - **FIS.** The trailing P/E is flattered by a non-operating gain.
  - **CHTR/CMCSA.** The fundamentals agree with the price.

#### Voice 6 — Macro / Regime

*Regime (`macro-regime`): TRANSITIONAL / bifurcated.* Week on week vs the 10-26 snapshot:
- **Rates:** 10y 4.96 → 4.98 (dated 10-29), 2y 4.65 → 4.61, spread 0.31 → 0.37
  (steepening, no inversion).
- **Volatility:** VIX 19.03 → 17.20.
- **Dollar:** DXY 121.40 → 121.32, softer and not firming, as the lens corrected.
  SEK/USD 9.9237, flat.
- **Crypto:** Fear & Greed 50 → 37.

*Named gaps:* no commodity-price and no credit-spread data. **The 10-27/28 FOMC outcome is not
in the snapshot.** `fed_funds_rate` still reads 3.75 dated 09-01 (62 days old), and US CPI is
the same age. A calm VIX and a flat 10-year suggest no shock, but that is inference, not data.
FX is dated 10-23.

- **BUY AZN.ST (holding), 5 (down from 6).** Low beta and USD-reporting suit an uncertain
  regime. Lower because the regime turned calmer, which reduces the premium on
  defensiveness. That is a regime-only downgrade, stated plainly.
- **BUY NVDA, 5.** A falling VIX, a non-inverted curve and a passed FOMC with no rate shock
  in the 10-year make a permissive backdrop for USD duration growth.
- **Only two picks.** The regime favours neither defensives nor cyclicals strongly this
  week.
- **Explicit regime calls (downgrades stated, not hidden):**
  - **Crypto: no adds.** ETH −14.4% and BTC −7.3% over 30 days, sentiment in Fear. I side
    with the lens's contrarian flag ("wrong side of the regime"), which is not a trim
    signal (D-c).
  - **Swedish property: binary on 11-04.** No picks before then.
  - **SHB:** a steeper curve helps, but 11-04 is event risk both ways.
- **SELL flags on macro alone: none.**

#### Voice 7 — Copycat / Smart Money

**Coverage:**
- **US:** SEC EDGAR returned 403 again (CIK mapping). **Zero US insider data.**
- **Sweden:** FI covered all 7 holding issuers cleanly; the S36 workaround held. There is no
  FI read for any candidate (WIHL, CATE, DIOS, AZA).
- **Institutions:** `MISSING: institutional ownership not fetched`.

**Cleaning:**
- Volvo Car AB rows are discarded (a different issuer).
- Hvied (ATCO) appears twice, "History" and "Revised" (158.13 vs 185.13); counted once.
- Louise Lindh (SHB) shows two identical 20,000 @ 147.7409 rows on 23/10. Last week's memo
  recorded her trade as 30,000 @ 147.70. That is either a duplicate or the 10/15-row window
  shifting. I count her once and do not size it (§9).

- **BUY VOLV-B.ST, 8.** The strongest single insider read in this system's record.
  - **Board member Helena Stjernholm's closely associated entity bought exactly 1,500,000
    shares across eight rows on 27/10, at ~309.0–311.8.** That is ~466M SEK (my
    arithmetic).
  - This **averages down**: the 1.3M-share July purchase was at ~359–361 (carried from the
    10-26 memo). She added more shares, in more money, 14% lower.
  - The round total means one decision executed in eight fills, not eight signals.
  - Invalidated by: any disposal from this holder.
- **BUY SHB-A.ST, 7.**
  - **Chairman Pär Boman (closely associated) bought exactly 1,600,000 shares on 27/10, at
    ~152.9–153.9.** That is ~245.6M SEK (my arithmetic).
  - It lands on top of last week's four-insider cluster (CEO, CFO, Deputy CEO and a board
    member, 21–23 Oct, carried from 10-26) and his own August cluster.
  - Against: he bought at ~153, within ~1.6% of today's price, so this is not bargain-hunting.
    And one large holder buying repeatedly is a different signal from several buying
    independently.
  - Invalidated by: a disposal by any of the five.
- **BUY ATCO-B.ST, 6 (up from 5).** The cluster widened this week:
  - CEO Vagner Rego: 6,400 @ 156.80 (26/10)
  - CFO Peter Kinnart: 4,000 @ 159.35 (27/10)
  - Already known: Deputy CEO Håkan Andersson 5,000 A @ 181.82; board member Johan Forssell
    (associated) 10,000 @ 158.65; management member Marcus Hvied 2,000
  - About 4.45M SEK in total (my arithmetic). Small money, but the breadth (CEO + CFO +
    deputy + board) is real.
  - **One correction to `thesis-review`:** it lists "CFO + Deputy CEO + 2 board members".
    The register shows the **CEO** too, and Hvied is management, not board.
- **BUY AZN.ST, 4.** Soriot 60,000 @ 121.02 GBP and Demare 2,500 on 14/09. Seven weeks old,
  nothing since. The CFO rows priced at 0.00 are vestings.
- **Reads that are not calls:**
  - **ABB.ST.** The freshest row is 14/08 (Terwiesch/Meline disposals, Jul–Aug). The May
    board "acquisitions" were six directors at an identical 78.42 CHF on one date. That
    looks like board-fee share allocation rather than open-market conviction (my reading).
    Stale both ways, so **no SELL**.
  - **INVE-A.ST.** Nodhäll bought 37,500 A and sold 20,284 B (net +17,216), mostly a
    share-class switch. Kidane bought 1,250 B. No call.
  - **ALFA.ST.** Nothing since CFO Ekström's 1,000 @ 547.49 on 11/09. The pattern is intact
    but quiet.
- **SELL flags: none.**

---

### 3b. Chairman's Top 5

Rank is reported for persistence only. It carries no evidential weight (S33).

#### #1 OPPORTUNITY: ABB.ST — ABB

**CATEGORY:** holding

**RANK HISTORY:** 65 now; 65 (10-26). 0 of 12 runs in the top 10.

**VOICES IN FAVOR (of selling):** Valuation, 3: the richest trailing/forward pair held
(32.86/32.33), with flat expected EPS.

**VOICES AGAINST / CAUTIOUS:**
- Fundamental: no SELL. ROIC 23.3%, op margin 18.7%.
- Growth: 14.3% growth at PEG 1.24 is no growth-lens sell.
- Defensive: ND/EBITDA 0.32, no risk case.
- Copycat: disposals 11+ weeks stale.
- Macro: no regime case.

**STRONGEST CASE FOR (selling):** Valuation's.
- The forward/trailing gap is still ~1.6%, so the market expects no EPS growth on 14.3%
  revenue growth. That is margin compression priced in.
- At 32.9x, ABB remains the most expensive line in the one ACT-rated sector.
- The `valuation` lens agrees: "Expensive and deteriorating-fundamentals-cheap-for-a-reason".

**STRONGEST CASE AGAINST (selling):** `thesis-review`'s, sharpened here.
- The stored BROKEN status rested on "richest valuation of the three, PEG 2.71". That fact
  is false today: PEG 1.24 vs ATCO 1.94 and ALFA 1.67.
- The other two original legs (the P/E "inversion" and the FCF unit error) were already
  shown to be artifacts (S32).
- What is left is the raw multiple, one of three legs.

**KEY DISAGREEMENT:** the `valuation` lens (Expensive, "consistent with BROKEN") against
`thesis-review` (WEAKENING). I weigh `thesis-review` more heavily on the **action** question,
for two reasons:
1. **The valuation lens never engages the comparative claim BROKEN was built on.**
   "Expensive" has been true since August. An expensive holding whose relative case has
   reversed is WEAKENING, and you hold a WEAKENING position without adding.
2. **The SELL's last structural support is gone.** Last week's SELL was "fresh judgement:
   richest multiple + ACT sector + funded destination".
   - The destination (VICI) deteriorated this week (#4).
   - Selling to cash makes concentration *worse*. Sweden rises from 47.6% to ~53.2% of the
     direct sleeve (15,668.95 / 29,432.95, my arithmetic), because ABB is the one
     non-Swedish industrial.

**Where I disagree with `thesis-review`:** it says the reversal should be put in front of
this test as fresh evidence. The PEG ~1.2 and the 1.6% gap were already in last week's memo.
The genuinely new input this week is the +6.3% price move, which slightly *strengthens* the
valuation objection. I am withdrawing the SELL because, re-read, last week's call was weaker
than its own memo admitted. No new data rescued ABB.

**DATA GAPS:**
- No EV/EBITDA.
- FCF is trailing-only and unit-mismatched (raw 0.13%, ~0.87% corrected per S32).
- No next print date (S37).
- No fresh insider read.

These are a moderate discount on a decision that is cheap to reverse.

**CHAIRMAN CONVICTION:** 5 (that holding is right)

**WHAT WOULD CHANGE THIS:** any of the following reinstates a SELL, decided fresh:
- forward P/E rising *above* trailing (EPS expected to fall)
- op margin below 16.9% (the 10-12 retire line)
- a new insider disposal cluster in the FI pull

**PORTFOLIO FIT:**
- ABB is 3,512.00 SEK, 10.66% of the 32,944.95 direct sleeve (my arithmetic on
  `portfolio`'s figures).
- Industrials 51.4% (ACT), Sweden 47.6% (ACT). ABB is Swiss, so it is the only industrial
  whose sale does not ease the country line.
- Holding without adding is the fit-consistent action.
- Record update for you: `portfolio.json` ABB.ST `thesis_status` BROKEN → WEAKENING, with
  the break conditions above.

**FINAL CALL: NO ACTION.** Hold 4 shares, add none. The SELL is formally retired, not left to
lapse.

**HORIZON:** Medium

#### #2 OPPORTUNITY: VOLV-B.ST — Volvo B

**CATEGORY:** holding

**RANK HISTORY:** 60 now; 62 (10-26). 0 of 12 in the top 10.

**VOICES IN FAVOR:**
- Copycat, 8: a board member's associated entity put 466M SEK in, averaging down 14%.
- Valuation, 6: forward 12.45 vs 16.14, PEG 0.85.
- Growth, 6: revenue +8.0% for a second run, from −13%.
- Outside the voices: `thesis-review` reads INTACT for the third consecutive sweep.

**VOICES AGAINST / CAUTIOUS:** Defensive: SELL 3, D/E 140.9 and ND/EBITDA 3.69 at beta 1.0.

**STRONGEST CASE FOR:** Copycat's, because the other evidence corroborates it.
- The insider who triggered the original thesis has now bought ~1.5M more shares below her
  own entry.
- Meanwhile the recovery she was betting on is showing up in reported fields: ttm revenue
  turned positive, and the forward multiple compressed from 14.6 to 12.45.
- Insider conviction and measured fundamentals now point the same way. Three months ago
  they did not.

**STRONGEST CASE AGAINST:** Defensive's. Volvo carries the most leverage of anything held,
sitting in the sleeve already rated ACT. A cyclical downturn hits revenue and the balance
sheet together. The insider's horizon and capacity are not yours.

**KEY DISAGREEMENT:** leverage risk vs a corroborated recovery. On merit I side with the
three BUY voices, because Defensive names no new deterioration (leverage is unchanged from
the purchase date). The disagreement does not need settling, though, because fit decides the
action.

**DATA GAPS:**
- No interest-coverage figure (`interest_expense` MISSING for every ticker).
- Volvo's leverage includes a financial-services arm. Whether the D/E is industrial or
  captive-finance debt is in no file, and it matters a lot for Defensive's case.
- No next print date (S37).

**CHAIRMAN CONVICTION:** 7 on merit

**WHAT WOULD CHANGE THIS:**
- A disposal by Stjernholm's entity, or ttm revenue turning negative again, cuts it.
- Industrials dropping below 45% (e.g. after the P3 queue lands) would make an add
  fit-feasible.

**PORTFOLIO FIT:**
- Industrials 51.4% ACT, Sweden 47.6% ACT (`portfolio`).
- Adding 5 shares (1,550.50 SEK) takes Industrials to ~53.6% and Sweden to ~49.9% (my
  arithmetic). It worsens both ACT lines.
- `thesis-review`'s point applies in reverse: if you ever add to the industrial sleeve,
  this is the name.

**FINAL CALL: HOLD-WATCH.** Hold all 13 shares and do not add now. This is a high-merit
opportunity resolved on concentration grounds, which is a correct output. **Record update for
you: VOLV-B.ST `thesis_status` TOO_EARLY → INTACT.** This is the third consecutive sweep
`thesis-review` reached it, and the break condition's 3-month clock has run out with the
recovery visible.

**HORIZON:** Medium

#### #3 OPPORTUNITY: NVDA — Nvidia

**CATEGORY:** watchlist

**RANK HISTORY:** 2 now; 2 (10-26). Top-10 in every run on record (11–12 consecutive, per
scout context).

**VOICES IN FAVOR:**
- Growth, 8: +105.9% on a 100% CAGR.
- Valuation, 7: forward compressing for a third week, to 12.86.
- Fundamental, 7: ROIC 59.2%, net cash.
- Macro, 5: permissive backdrop.

**VOICES AGAINST / CAUTIOUS:**
- Defensive: beta 2.216, part of a crowded AI-capex trade.
- Fundamental's own caveat: FCF 0.85% vs a 3.87% earnings yield.

**STRONGEST CASE FOR:** Valuation's. For three weeks the market has paid less per unit of
expected earnings (13.45 → 13.26 → 12.86) on unchanged measured growth, with no suspect flag
and a PASS screen.

**STRONGEST CASE AGAINST:** Fundamental's. Only ~22% of earnings converts to free cash (USD
over USD, so real). Some of the "cheap forward" is cheap on accruals and working capital until
cash catches up.

**KEY DISAGREEMENT:** the cheapest measured growth vs unproven cash conversion. Unchanged and
not reconciled. **The 11-17 print is the test.** It is now dated, thanks to this sweep's
widened calendar.

**DATA GAPS:**
- No revisions, backlog or US insider data.
- 13F not fetched.

Moderate discount.

**CHAIRMAN CONVICTION:** 6

**WHAT WOULD CHANGE THIS:**
- Raises it: FCF yield moving toward the earnings yield at 11-17.
- Kills it: forward P/E rising above trailing.

**PORTFOLIO FIT:**
- `portfolio`: US Tech diversifies sector (0% today) and country (0% direct), but adds to an
  all-large-cap tier.
- One share is 213.66 × 9.9237 = **2,120.30 SEK**, about 0.95% of capital (my arithmetic).
- Bought within the queue (§5), it helps pull Sweden and Industrials below 45%.

**FINAL CALL: BUY** — 1 share. **Execution note:** no idle capital is confirmed beyond the
845.43 SEK ISK figure (`portfolio`). It is funded by P3, after gold tranche 2 and AZN. If P3
lands before 11-17 you buy into the print. That is acceptable at a Medium horizon. Do not
time it.

**HORIZON:** Medium

#### #4 OPPORTUNITY: VICI — Vici Properties

**CATEGORY:** new candidate (`source=new`: not held, not watchlisted; in the funnel since
2026-08-25, not first-seen)

**RANK HISTORY:** 28 now; 13 (10-26); 9 (10-19). Top-10 in 9 of 12 runs, the last three all
outside.

**VOICES IN FAVOR:** none at BUY this week.

**VOICES AGAINST / CAUTIOUS:**
- Valuation: BUY withdrawn (EPS −17%, ND/EBITDA 5.46).
- Contrarian: BUY withdrawn (an unexplained fundamentals change).
- Defensive: leverage rising.

**STRONGEST CASE FOR (still holding interest):** what is left of Valuation's original case.
8.18x forward, a 7.52% dividend, revenue +5.8% on a 15.5% CAGR, PASS. If the EPS drop is a
one-off non-cash item (common for REITs), the case comes back intact.

**STRONGEST CASE AGAINST:** this sweep's own data. A +2.1% price move pushed trailing P/E up
22% (9.25 → 11.32). Net margin fell 11pp. Leverage moved most of the way toward Valuation's
own invalidation line of 6.0.

**KEY DISAGREEMENT:** an accounting item or a real deterioration? No file can tell. Without
FFO/AFFO, the GAAP fields are the only evidence, and they deteriorated.

**Correction to the relayed scout context:** the context called VICI's rank fall "purely
mechanical, not a fundamentals deterioration". That was true on 10-26. It is not true today.

**DATA GAPS:**
- No FFO, AFFO, lease coverage or print date. VICI is not in the calendar file even with the
  widened fetch.
- No US insider data.

Heavy discount.

**CHAIRMAN CONVICTION:** 3 (on the BUY case)

**WHAT WOULD CHANGE THIS:** VICI's Q3 release showing the EPS drop is non-cash (an impairment
or allowance) with AFFO intact. That needs the `pdf` skill or a user relay.

**PORTFOLIO FIT:**
- `portfolio`: diversifies sector and country, concentrates tier.
- It no longer needs a funding slot, because the ABB proceeds it was earmarked for no longer
  exist (#1).

**FINAL CALL: HOLD-WATCH.** Downgraded from BUY. It leaves the funding queue.

**HORIZON:** Medium

#### #5 OPPORTUNITY: APP — AppLovin

**CATEGORY:** new candidate (`source=new`; in the funnel every run since 2026-08-25, not
first-seen)

**RANK HISTORY:** 3 now; 1 (10-26). Rank 1 in 10 of the prior 11 runs; top-10 in all 12.

**VOICES IN FAVOR:**
- Fundamental, 6: ND/EBITDA 0.09 and ROIC 65.5%, on the same consistency test as MA.
- Growth, 5: +52.8%, forward prices EPS +54%.
- Contrarian, 5: price vs fundamentals divergence.

**VOICES AGAINST / CAUTIOUS:**
- Defensive: beta 2.557.
- Valuation (lens): "the mispricing case partly rests on a levered balance sheet".
- Macro: none.

**STRONGEST CASE FOR:** Fundamental's correction of last week.
- The "leverage" objection fails the Council's own MA standard. Net debt is 0.09x EBITDA.
- So this is a 77.7%-op-margin business converting ~73% of earnings to FCF, at 11.4x
  forward, after three down weeks.

**STRONGEST CASE AGAINST:** Defensive's, plus the S29 gap.
- The price has fallen 279.29 → 254.91 (−8.7%, my arithmetic) to 6% of range, and no
  fetched field explains why.
- The print is in **two days** (11-04). Buying now is a bet on one event: a short-horizon
  trade, which this system has no edge in and which CLAUDE.md caps.

**KEY DISAGREEMENT:** is the fall an overshoot (Contrarian) or the market pricing something
the fields do not yet show? Not resolvable today. It resolves in 48 hours.

**DATA GAPS:**
- No 52w endpoints beyond range % (S29).
- No US insider data.
- No revenue-concentration data.

Heavy discount on timing, light on business quality.

**CHAIRMAN CONVICTION:** 5 on merit

**WHAT WOULD CHANGE THIS:** the 11-04 print.
- Forward estimates holding (forward stays well below trailing) with op margin above 70%
  makes it a BUY candidate next sweep.
- Forward rising toward trailing ends the case.

**PORTFOLIO FIT:**
- US Communication Services diversifies sector and country, concentrates tier
  (`portfolio`).
- One share is 254.91 × 9.9237 = **2,529.65 SEK** (my arithmetic).
- No capital is free after the §5 queue.

**FINAL CALL: HOLD-WATCH.** Re-decide next sweep with the print in the data.

**HORIZON:** Medium

### 3c. Other SELL recommendations on current holdings, and standing calls

**Should you sell anything? No. The Chairman makes no SELL call this sweep.** Voice SELLs
that did not place:
- **ABB.ST, Valuation SELL 3:** overruled in #1.
- **VOLV-B.ST, Defensive SELL 3:** overruled in #2. Three voices disagree on the same data,
  and the leverage it cites is unchanged since purchase.
- **SHB-A.ST, Growth SELL 3:** overruled. Insider evidence strengthened again (Boman
  1.6M shares), and the revenue decline did not widen (−2.1%, the same as last week).
- **INVE-A.ST:** `thesis-review` says "would I buy today? NO" on valuation (97% of range).
  No voice issued a SELL. The D-b durable hold stands until a NAV figure exists.
- **ALFA.ST, ATCO-B.ST, AZN.ST, the funds, Xetra-Gold, BTC0E.AS, ETH:** no SELL flag. ETH
  cannot be sold cleanly while P1 is open.

**Standing BUYs, not re-ranked:**
- **AZN.ST — BUY 1 share. Chairman conviction 7, up from 6.**
  - The 10-30 print passed both pre-set tests: op margin 29.6% (≥20%) and PEG 1.28 (≤1.6).
  - Four voices back it: Defensive 7, Valuation 6, Macro 5, Copycat 4. `thesis-review`
    reads INTACT, would buy YES.
  - **Fit:** bought alone, one share takes Healthcare/UK from 41.8% to ~44.7% (15,484.50 /
    34,665.45, my arithmetic). That is just under 45%. Inside the full queue it ends ~40.4%.
- **SHB-A.ST — BUY 10 shares, conviction 4 (down from 5). Last in the queue, after 11-04.**
  - Copycat's evidence strengthened.
  - The price rose +5.5% to 95% of range, which thins the cushion last week's sizing relied
    on. `thesis-review` says HOLD ONLY and would not initiate fresh.
  - I keep the BUY because a ~245M SEK chairman purchase at ~153 is the kind of evidence
    this system rarely gets. I cut conviction because valuation got worse.
  - Waiting until after 11-04 is sequencing. SHB is last in the queue anyway, and P3 takes
    days to settle. It is not a forecast of the decision.
  - **Fit:** bought alone, Sweden rises to ~49.9%. Bought last, it ends ~44.9% (my
    arithmetic).
- **ATCO-B.ST:** Fundamental 7 and Copycat 6 give a real merit case to add. Fit says
  Industrials ACT, so hold and do not add. `thesis-review` agrees, with Volvo as the better
  add if one is ever made.

**Considered for the Top 5, not placed:**
- **V / MA** (Fundamental 8/7). Both at 95% of range, with Valuation's objection
  (PEG 1.87/1.66) unanswered.
- **FIX** (Growth 6). Third clean run, but one share is now 1,326.23 × 9.9237 = **13,161
  SEK**, about 5.9% of capital, in Industrials. HOLD-WATCH on fit, as last week.
- **NOVO-B.CO** (Defensive 4, Contrarian 4). Two independent lenses, both low conviction.
  Watch.
- **WIHL/CATE/DIOS.** `portfolio` names them as the only true diversifiers in the set (real
  estate, small/mid-cap). No voice picked them, on ~10x leverage, and the Riksbank on 11-04
  is the observable. Re-test next sweep with the decision known. Diversification fit does
  not override merit.
- **GOOGL** (Contrarian 3). An argued pull-in, but one voice at conviction 3 does not make
  a Top-5 name.

---

## 4. Portfolio health scorecard

From this sweep's `portfolio` lens, verbatim in substance. Total ≈ **224,121 SEK**.

| Dimension | Rating | Number |
|---|---|---|
| Asset allocation vs targets | ACT | Equity 72.58% vs 80% (−7.42pp, driven almost entirely by the cash overweight from unexecuted P3); crypto 10.01% on target; cash 11.99% vs 5% (+6.99pp); gold 2.54% vs 5% (−2.46pp); FI/alt 2.89% vs 0% (+2.89pp, Auto 3's mixed classification) |
| Equity sector concentration | ACT / WATCH | Industrials 51.4% ACT, Healthcare 41.8% WATCH, Financial Services 6.8% OK. Measured on the ~20% resolvable direct sleeve only; UNKNOWN for the ~80% in Avanza Global / Auto 3 (no look-through) |
| Geography | ACT / WATCH | Sweden 47.6% ACT, UK 41.8% WATCH. The same single name (AZN.ST) drives both Healthcare and UK, a single-name effect, not diversification |
| Currency | WATCH | No fund look-through; directionally more non-SEK exposure than listing currency suggests |
| Single-position concentration | OK | AZN.ST largest true single company at 6.14%, under the 15% cap. Avanza Global 53.5% flagged for transparency only (a diversified fund) |
| Institution concentration | ACT | Avanza 83.3% vs the 80% cap. Custody-segregation caveat; no wrapper change recommended, because the alternative is worse |
| Fee drag | OK | 187.12 SEK/yr, ~0.0835%, well under the 0.4% cap. Closed lever |
| Wrapper efficiency | OK | Clean, matches CLAUDE.md "DONE 2026-08-03" |
| Drawdown-tolerance fit | WATCH | S26 backtest −20.62% max DD inside −30%, but that window's worst equity shock was only −19.14%. Not genuinely stress-tested |

Exposure: Equity 162,658.55 / Crypto 22,436.54 / Cash 26,860.15 / FI-alt 6,476.40 / Gold
5,689.22 = 224,120.86 SEK.

**New data-quality flag from `portfolio`:** the Avanza Global and Auto 3 marks are 14–15
weeks stale (07-24/07-28). They are ~80% of the equity sleeve, and nothing refreshes them
(§9).

**Provisional, per `investor_profile.json` (read this session):**
- `primary_goal` is "nature UNCERTAIN", on a 3–7y SOFT horizon.
- `constraints.exclusions` is `[]` ("None stated yet").
- `reference_targets` is stale at 85/10/0/5 with no `gold_pct` (S35).
- The −30% tolerance is untested against a real shock (S26).

**PROPOSED target allocation** (from `portfolio`; memo content only, written to no file):
**Equity 80 / Crypto 10 / Cash 5 / Fixed income 0 / Gold 5.**
- It was derived fresh from `investor_profile.json`: −30% max drawdown, soft 3–7y horizon,
  60/30/10 tier mapping, near-zero FI direction, and the pre-approved 5% gold carve.
- It is **identical** to `portfolio.json.targets` and to last sweep's independent
  derivation. That makes this the **second consecutive confirmation by the same method**,
  the bar S35 was waiting for.
- To close it, say "apply S35". That updates `reference_targets` to 80/10/0/5, adds
  `gold_pct: 5`, or better, replaces the duplicated numbers with a pointer to
  `portfolio.json.targets`.
- Glidepath does not apply (the horizon is soft). No calendar de-risking.

---

## 5. Headline calls

Each needs a decision this session.

1. **ABB.ST: the SELL is retired. Hold 4 shares, add none.** *Confidence Low, horizon
   Medium.* Update `thesis_status` BROKEN → WEAKENING in `portfolio.json`. A SELL comes back
   only on the three observables in #1.
2. **Execute P3, unexecuted for a 13th sweep, then run this queue in order.** *P3: confidence
   High (arithmetic), horizon Long. Queue: Medium confidence, Medium horizon.* Net deployable
   ≈ 14,910 SEK (14,651.06 PayPal × 0.96 + 845.43 ISK cash; my arithmetic on `portfolio`'s
   figures). In order:
   - (a) Gold tranche 2: ~5,517 SEK of Xetra-Gold, which closes the 5% target gap
     (`portfolio`)
   - (b) AZN.ST: 1 share, 1,720.50
   - (c) NVDA: 1 share, ~2,120.30
   - (d) SHB-A.ST: 10 shares, 1,557.50, after 11-04
   - (e) The remainder, ~3,995, to Avanza Global

   After the queue, the direct sleeve reads Industrials ~44.2%, Sweden ~44.9%, Healthcare
   ~40.4% (my arithmetic). Both ACT lines drop just below 45%.

   This differs from `portfolio`'s suggested split (gold + ~9,393 to Avanza Global).
   `portfolio` allocated on diversification alone. The Chairman routes ~5,400 of the equity
   portion to three merit-backed BUYs. Neither split resolves the Avanza institution ACT
   (83.3%). That tension stays flagged, not papered over.
3. **VOLV-B.ST: hold 13, no add. Update `thesis_status` TOO_EARLY → INTACT.** *Confidence
   Medium, horizon Medium.* This is a `portfolio.json` record edit for you; no agent makes
   it.
4. **Crypto: read the live Avanza value of your 150 BTC0E.AS units (D-c), and close either P1
   or the sizing decision.** *Confidence High (it gathers information, it does not forecast),
   horizon Long.*
   - The trim trigger is now **~14,802 SEK** (~98.7 SEK/unit). My arithmetic:
     11,405.53 + V > 0.115 × (213,089.86 + V).
   - This is the fourth sweep with no certificate price.
   - `thesis-review`: "don't let another sweep pass without someone closing P1 or D3".
5. **Say "apply S35".** *Confidence High, horizon Long.* Two consecutive identical
   derivations. Nothing analytical is left to do.

---

## 6. Open actions vs open decisions

### Open actions (things to go do), by ID

| ID | Status | Action |
|---|---|---|
| **P3** | decided — pending execution (13th sweep) | Convert 1,177.49 USD + 266.88 EUR (~14,651 SEK at this sweep's FX) inside PayPal, move it to the ISK, then zero the PayPal holdings in `portfolio.json`. It now blocks gold tranche 2, AZN, NVDA and SHB. |
| **P1** | blocked (on you) | ETH cost basis. Blocks any ETH sale or K4, and keeps the no-adds freeze. |
| **P9** | open | Delete the phantom AZN OPENING row in the Excel Transactions tab. |
| **P10** | open | Confirm one 5,000 SEK deposit or two (08-17 vs 08-22). |
| **S35** | open, ready | "apply S35" (§4). |
| **S27** | blocked (outside repo) | Re-sync the scheduled prompt: remove the two stale premises (11th-plus occurrence this sweep). |
| **S26** | open | Shock-window backtest. |
| — | record updates | ABB.ST BROKEN → WEAKENING; VOLV-B.ST TOO_EARLY → INTACT; DE000A0S9GB0 TOO_EARLY → INTACT (`thesis-review`: never time-gated; the missing price is a pricing gap, not a maturity gap; the Chairman concurs). |

### Open decisions (forks)

**D-a — ABB.ST.** Chairman pick: Option 1.
- *Option 1 — hold, retire the SELL.* Trade-off: you keep the richest multiple held, in an
  ACT sector, on a growth-adjusted case.
- *Option 2 — execute the old SELL to cash anyway.* Trade-off: Sweden rises to ~53.2% and
  cash, already 7pp over target, grows. You also act on a case with one of three legs left.
- *Option 3 — rotate ABB → Volvo.* Trade-off: it buys the stronger insider/valuation
  industrial, but Sweden jumps to ~58.2% and leverage rises. Rule this one out.

**D-b — INVE-A.ST NAV.** Unchanged. Durable hold (Option 1) until you record a NAV figure.
INVE is at 97% of range, and the insider rows are a share-class switch.

**D-c (= D3) — crypto sizing.**
- *Option 1 — read the Avanza value now (one minute).* Trade-off: none worth naming.
- *Option 2 — record that value as the new mark and scale it weekly by CoinGecko BTC spot.*
  Trade-off: a proxy, with small tracking error for a 0%-fee backed note.
- *Option 3 — wait for a feed.* Trade-off: the fifth unsizable sweep. The ticker has 404'd
  every attempt.
- **Pick: Option 1, then Option 2 as the standing method.**
- Directionally, BTC is −1.9% week on week (71,335 → 69,952 EUR) and ETH −1.2%. Nothing
  points toward the trigger. Direction is not a mark.

### Structural decisions (non-stock)

Levers 1–2 are closed and not re-flagged.

**ACTION:** Execute P3. Recommended; this system trades nothing.
- **POSITION:** ~14,651 SEK in PayPal (11,685.06 USD-leg + 2,966.00 EUR-leg at
  9.9237/11.1136), outside any wrapper.
- **TARGET:** the ISK, split per §5 call 2.
- **REASON:** the binding funding constraint on four BUYs plus the gold gap, and a recurring
  ~4% spread on every inflow.
- **THESIS STATUS:** decided by you 2026-08-17 (Option A).
- **WHAT CHANGED:** the count (13th sweep) and the queue (VICI leaves).
- **BREAK CONDITION:** a fee-free route appears, or the realised spread is materially above
  4%.
- **CONFIDENCE:** High
- **HORIZON:** Long

**ACTION:** Gold tranche 2, ~5,517 SEK of Xetra-Gold (DE000A0S9GB0), first call on P3.
- **POSITION:** 5,689.22 SEK at cost (2.54%). No live price.
- **TARGET:** 5% (`portfolio.json.targets`), ceiling 7.5%.
- **REASON:** structural crash hedge, under target.
- **THESIS STATUS:** INTACT per `thesis-review` (stored TOO_EARLY; record update above).
- **WHAT CHANGED:** nothing. It is funding-bound.
- **BREAK CONDITION:** S26 shows gold adds nothing at 5%.
- **CONFIDENCE:** Medium
- **HORIZON:** Long

---

## 7. Cost of being wrong

| Headline call | If wrong | Realistic SEK downside | Recoverable? |
|---|---|---|---|
| 1. Hold ABB (SELL retired) | Margin compression shows up, ABB −25% | ~878 (4 × 878 × 0.25) | Yes. It can be sold any day, tax-free in the ISK. |
| 2. P3 + queue | The spread is certain; then gold −20%, AZN −30%, NVDA −40%, SHB −20%, Global −30% | ~586 spread + ~1,103 + ~516 + ~848 + ~312 + ~1,199 | The spread, no (and it recurs while P3 waits). The positions, yes, with time. Total ~4,560, ~2.0% of capital. |
| 3. Hold Volvo, no add | (a) recovery runs, +20% foregone on 5 shares; (b) leverage bites, −30% on 13 held | (a) ~310 foregone; (b) ~1,209 | Yes, both. |
| 4. Crypto read / no trim at an unknown mark | The sleeve is above the trigger, then crypto halves | ~11,218 on the 22,436.54 sleeve; only the overweight slice was avoidable | The overweight part, yes. Whether the whole loss fits −30% is S26's open question. |
| 5. Apply S35 | A target you later want different | 0 SEK; a one-line revert | Yes. |

All figures are my arithmetic on this sweep's prices and FX.

---

## 8. Timing collisions

From `data/cache/calendar/20261102-events.json`. Caveats: macro dates were last verified
2026-08-03, and US/SE CPI dates are missing. This sweep's fetch was widened beyond holdings,
so candidates now have dates (a partial S37 fix).

- **11-03: SMCI reports.** No call involves it.
- **11-04: Riksbank decision + MPU, the main collision.**
  - APP, FIS and TPL report the same day.
  - Relevant to SHB (the queued BUY, sequenced after) and to WIHL/CATE/DIOS (re-test next
    sweep).
  - APP's HOLD-WATCH is partly *because* of its 11-04 print.
- **11-06: CHTR reports.** No call.
- **11-10: Riksbank minutes.** **11-17: NVDA reports**, inside the likely P3 execution
  window. Buying before means owning the print. Acceptable at a Medium horizon; do not time
  it.
- **11-30: Riksbank FSR.** **12-08/09: FOMC.** **12-09: AVGO reports.** **12-16: Riksbank
  decision.** **12-23: MU reports.**
- **S37, still partly open.** The five Swedish holdings (SHB, VOLV, ATCO, ALFA, ABB)
  returned already-past dates, and INVE returned none. Their next prints are unknown, so
  ABB's three reinstatement observables (#1) cannot be dated.
- **The 10-27/28 FOMC happened, but its outcome is not in the snapshot** (fed funds dated
  09-01).

---

## 9. Data gaps for `meta`

Ordered by what each cost this sweep. Surfaced, not fixed.

1. **VICI's fundamentals changed and the pipeline labelled it "mechanical".** No step diffs
   a candidate's fundamentals week on week. A Top-5 BUY's destination case broke, and it
   was caught only by hand-comparing against last week's memo prose. A per-candidate
   field-delta column (P/E, margin, ND/EBITDA vs prior run) in the candidates CSV or
   `candidate_history.csv` would surface it mechanically.
2. **`source=new` showed 0 of 34 genuinely first-seen this sweep, the worst reading yet.**
   The label means "not on the watchlist". A `first_seen` column would make Pillar-1
   honest.
3. **Fund NAVs are 14–15 weeks stale on ~136k SEK** (~80% of equity). Nothing refreshes
   them. This is new from `portfolio`, and it merits an S-item.
4. **The macro block runs at two speeds.** Fed funds and US CPI are 62 days old, and the
   10-28 FOMC outcome is missing. FX is 10 days old. The Riksbank rate is fresh (10-30).
5. **BTC0E.AS and Xetra-Gold have no price for a 4th+ sweep** (Xetra-Gold returned 429 and
   404 this time, under both the ISIN and `.SG`).
6. **FI de-duplication.** Lindh shows two identical 20,000-share rows that conflict with
   last week's 30,000. Hvied's History/Revised pair still disagrees on price. Board-fee
   allocations (ABB, May) look the same as open-market buys. Counts need ISIN + status
   filtering and a compensation flag.
7. **FI and US-insider scope.** No FI read for candidates (exact names needed: "Wihlborgs
   Fastigheter", "Catena", "Diös Fastigheter", "Avanza Bank Holding"). SEC EDGAR has
   returned 403 for weeks, so there is zero US insider data on 10 of the 15 focus
   candidates.
8. **Net margin above op margin as a quality flag.** FIS (27.6 vs 20.7) and GOOGL (50.0 vs
   31.8) carry trailing P/Es probably flattered by non-operating gains. Scout could flag
   `margin_pct > op_margin_pct` as a "trailing-EPS quality" warning, the same way
   `suspect` works.
9. **S32 persists.** TSM `fcf_yield_pct` is 57.12%, unflagged. AZN/ABB FCF, P/S and P/B are
   still unit-mismatched.
10. **S21:** AZN.ST `forward_pe` is missing for the 11th run.
11. **Lens-level slips caught here:**
    - `thesis-review` presented ABB's PEG reversal as new; it was already in the 10-26 memo.
    - `thesis-review` omitted ATCO's CEO from the insider cluster.
    - The relayed scout context called VICI's fall purely mechanical.
12. **Still missing everywhere:**
    - EV/EBITDA
    - FFO/AFFO (VICI)
    - interest coverage (every ticker)
    - Volvo's industrial-vs-financial-services debt split
    - bank NIM and credit metrics (SHB)
    - property NAV/EPRA (WIHL/CATE/DIOS)
    - commodity and credit-spread series

---

## 10. Learning notes

- **A reversal can be old news.** `thesis-review` was right that ABB's stored status was
  stale. But the evidence for that (PEG ~1.2) was already on the table last week. The honest
  question was not "what is new?" but "was last week's call right on what it already had?"
  Separating those two stops a fresh-looking argument from getting credit it has not earned.
- **Apply a test the same way to every name.** Last week the Council excused MA's high
  debt-to-equity (buybacks, low net debt) but held APP's high ROE against it. APP's net debt
  is actually *lower* (0.09x EBITDA vs 0.59x). The same rule applied to both changed a
  "decline" into a BUY 6. Inconsistency between names is a quiet way to bias a screen.
- **Net margin above operating margin is a warning sign.** If a company earns more after
  interest and tax than from its operations, something outside the business (a sale, an
  investment gain) is in the earnings. FIS's 5.9x P/E and GOOGL's 14.6x both carry that
  marker, so the "cheap" trailing multiple is partly a one-off.
- **Round numbers in an insider register mean one decision.** Volvo's eight rows sum to
  exactly 1,500,000 shares, and Handelsbanken's to 1,600,000. Each is one order filled in
  pieces. That is still a big signal, but count it once, not eight times.

---

`journal` **must run next.** An unlogged memo is invisible to the next session and can never
be reconciled. Then run `python scripts/decisions.py record --picks
data/picks/2026-11-02-picks.csv`, followed by `python scripts/decisions.py basis --write`.
